TABLE 1

Comparison of physiological, biochemical and admission data in patients who survived and those who did not

All patientsSurvivorsNon-survivorsp-value
Subjects, n1405882
Age, mean±sd71.24±11.166.1±12.474.4±9.0<0.001
Male, n (%)91 (65)34 (59)55 (67)0.433
Clinical Frailty Score, median (range)3 (1–7)2 (1–5)4 (1–7)<0.001
CPAP/HFNO duration days, median (range)3.5 (1–24)4 (1–24)3.5 (1–18)0.642
CPAP/HFNO well tolerated, n (%)120 (86)50 (85)67 (79)0.098
Comorbidities, n (%)
 HTN83 (59)33 (57)50 (61)0.909
 Diabetes mellitus40 (29)15 (26)25 (30)0.685
 COPD36 (26)9 (16)27 (33)0.031
 Asthma15 (11)10 (17)5 (6)0.026
 Home NIV/CPAP15 (11)5 (9)10 (12)0.568
 Previous cancer14 (10)2 (3)12 (15)0.037
 IHD38 (27)7 (12)31 (38)0.001
 Smoking history70 (50)24 (41)46 (56)0.127
 Obesity52 (37)17 (29)35 (43)0.022
Laboratory results, mean±sd
 Admission WCC ×109·L−19.7±4.47.8±3.410.6±5.10.185
 Admission lymphocyte count ×109·L−11.02±0.641.07±0.890.98±0.690.631
 Admission C-reactive protein mg·L−1155±95.5154±76147±1070.129
Observations pre-CPAP/HFNO, mean±sd
 Respiratory rate25.9±6.025.3±5.928.7±6.80.003
 Heart rate89.4±17.089.9±19.197.3±21.90.147
 Oxygen saturations88.8±6.986.9±8.187.0±5.30.387
PaO2/FIO2 ratio76.5±39.178.6±35.975.2±41.30.652
CPAP/HFNO settings, mean±sd
 Starting CPAP PEEP9.2±1.88.4±2.19.7±1.90.012
 Starting CPAP FIO266.9±17.559.6±16.771.1±16.70.002
 Starting HFNO flow rate L·min−154.0±10.153.9±10.154.1±10.30.887
 Starting HFNO FIO270.0±14.670.4±15.969.7±14.00.966

CPAP: continuous positive airway pressure; HFNO: high-flow nasal oxygen; HTN: hypertension; NIV: noninvasive ventilation; IHD: ischaemic heart disease; WCC: white cell count; PaO2: arterial oxygen tension; FIO2: inspiratory oxygen fraction; PEEP: positive end-expiratory pressure.